Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“MedCity is invaluable among the many sources of industry reporting because the team endeavor to bring the truly new, and innovative opportunities and developments to light.”

Ken Kirby, President, Transdermal Delivery Solutions Corp


Sign up for our daily newsletter


Drug developer ChanRx closes series A investment, hires CEO

November 21, 2011 11:31 am by | 0 Comments

Drug developer ChanRx has closed a series A round of investment that it will use to fund clinical trials of a pharmaceutical to treat atrial fibrillation.

The Cleveland-area company, which was spun off from pharmaceutical testing firm ChanTest in 2006, didn’t specify the amount of the investment in a prepared statement. The round was led by Austin, Texas-based Sante Ventures with additional funding from Arthur “Buzz” Brown, founder and CEO of ChanTest.

Brown declined to reveal the amount of the investment.

ChanRx is developing vanoxerine, an anti-arrhythmia drug that has demonstrated an ability to restore normal heart rhythm in a human clinical study.

Advertisement

The drug has been shown to be safe in six phase 1 clinical trials. A phase 2a trial showed the drug to have promise in treating patients with paroxysmal atrial fibrillation, a periodically occurring type of irregular heart rhythm. A phase 2b trial is ChanRx’s next step, which the company hopes to begin early next year and wrap up around the end of the year, Brown said.

ChanRx is hoping its phase 2 data will be strong enough to entice a big pharmaceutical company to partner for a pivotal phase 3 trial, Brown said. ChanRx will need to establish a partnership — or land a large venture round — to afford the expensive trial.

Even under the best-case scenario, the drug is likely four years or so away from reaching the market.

Along with the funding announcement, the company said it has hired R.K. Khosla as its CEO. Khosla previously was CEO of stent company Peritec Biosciences.

Last year, ChanRx secured a $250,000 investment from Cleveland nonprofit venture development group JumpStart.

 

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Brandon Glenn

By Brandon Glenn MedCity News

Brandon Glenn is the Ohio bureau chief for MedCity News.
More posts by Author

0 comments